Eli Lilly and Co (LLY.N)
6 Dec 2013
|Market Cap (Mil.):||$57,042.27|
|Shares Outstanding (Mil.):||1,126.65|
- Eli Lilly and Co said on Thursday it would not seek approval for edivoxetine, its experimental drug to treat major depression, after it failed to meet its primary goal in three late-stage trials.
Dec 5 - Eli Lilly and Co said on Thursday it would not seek approval for edivoxetine, its experimental drug to treat major depression, after it failed to meet its primary goal in three late-stage trials.
Dec 5 - Eli Lilly and Co on Thursday said its experimental drug to treat major depression failed to meet it primary goal in three late-stage trials and the drugmaker will not seek approval of the medicine for that condition.
FRANKFURT - Swiss drugmaker Novartis is ready to sell its animal health subsidiary and has opened its books to Bayer and other rivals interested in a business that could change hands for more than 3 billion euros ($4.1 billion), sources familiar with the matter told Reuters.
CHICAGO - Eli Lilly & Co.'s Elanco Animal Health unit will raise the price of its beta-agonist feed supplements by 2 to 3 percent on November 26 amid strong demand from beef feedlots, a company spokeswoman told Reuters on Wednesday.
CHICAGO, Nov 13 - Eli Lilly & Co.'s Elanco Animal Health unit will raise the price of its beta-agonist feed supplements by 2 to 3 percent on Nov. 26 amid strong demand from beef feedlots, a company spokeswoman told Reuters on Wednesday.
Oct 23 - Eli Lilly and Co on Wednesday reported better-than-expected quarterly earnings, helped by cost cuts and strong growth of its drugs for depression, diabetes and cancer. ,
(The following statement was released by the rating agency) CHICAGO, October 11 (Fitch) Fitch Ratings has affirmed Eli Lilly & Co. Inc.'s (Lilly) ratings, including the Issuer Default Rating (IDR) at 'A'. The Rating Outlook has been revised to Stable from Negative. A full list of ratings follows at the end of this release. The ratings apply to approximately $5.3 billion of debt at June 30, 2013. KEY RATING DRIVERS Fitch believes Lilly will maintain a credit profile supportive of its 'A' rat
COPENHAGEN - Danish drugmaker Novo Nordisk A/S has lost two contracts to supply a U.S. pharmacy group with its insulin and diabetes treatments, taking a bite out of expected earnings.
(Adds dateline, rewrites first paragraph, adds analyst comment, updates shares)
|Takeda Pharmaceutical Company Limited (4502.T)||¥5,070||+75.00|
|Johnson & Johnson (JNJ.N)||$94.09||+1.12|
|Pfizer Inc. (PFE.N)||$31.48||+0.23|
|Novartis AG (NOVN.VX)||CHF70.15||0.00|
|Merck & Co., Inc. (MRK.N)||$49.39||+0.58|
|Abbott Laboratories (ABT.N)||$37.53||+0.61|
|Sanofi SA (SASY.PA)||€74.37||+0.24|
|AstraZeneca plc (AZN.L)||3,489.00p||+19.00|
|GlaxoSmithKline plc (GSK.L)||1,605.00p||+8.00|
|Bristol-Myers Squibb Co (BMY.N)||$50.68||-0.12|
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (LLY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: Pechala's Reports
Eli Lilly and Co: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.